← Back to Screener
Purple Biotech Ltd. American Depositary Shares (PPBT)
Price$2.97
Value ScoreB
Growth ScoreD
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-20.48%
Price vs S&P 500 (4W)-3.49%
VGM Score51.49
Market Capitalization$20.26M
All Metrics
Book Value / Share (Quarterly)$0.01
P/TBV (Annual)3.48x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.00
Price vs S&P 500 (YTD)-19.96%
Net Profit Margin (TTM)-2777.90%
EPS (TTM)$-0.02
10-Day Avg Trading Volume0.08M
EPS Excl Extra (TTM)$-0.02
EPS (Annual)$-0.03
ROI (Annual)-264.97%
Net Profit Margin (5Y Avg)-3987.45%
Cash / Share (Quarterly)$0.00
Revenue Growth QoQ (YoY)0.00%
ROA (Last FY)-150.16%
Revenue Growth TTM (YoY)0.00%
EBITD / Share (TTM)$-0.02
ROE (5Y Avg)-85.27%
Operating Margin (TTM)-430.20%
Cash Flow / Share (Annual)$-0.00
P/B Ratio0.71x
P/B Ratio (Quarterly)0.65x
Net Income / Employee (Annual)$-2,638,600
EV / Revenue (TTM)1.48x
Net Interest Coverage (TTM)-0.86x
ROA (TTM)-99.09%
EPS Incl Extra (Annual)$-0.03
Current Ratio (Annual)1.27x
Quick Ratio (Quarterly)1.48x
3-Month Avg Trading Volume2.56M
52-Week Price Return-45.24%
Revenue / Employee (TTM)$100,000
Tangible BV / Share (Quarterly)$0.00
P/S Ratio (Annual)6.86x
Asset Turnover (Annual)0.07x
52-Week High$5.70
Operating Margin (5Y Avg)-3437.90%
EPS Excl Extra (Annual)$-0.03
CapEx CAGR (5Y)-54.63%
Tangible BV CAGR (5Y)-47.48%
26-Week Price Return-9.09%
Quick Ratio (Annual)1.25x
13-Week Price Return-9.09%
Total Debt / Equity (Annual)0.03x
Current Ratio (Quarterly)1.48x
Enterprise Value$1.48M
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-59.22%
Revenue / Employee (Annual)$100,000
Pretax Margin (Annual)-567.70%
Cash / Share (Annual)$0.01
3-Month Return Std Dev47.32%
Net Income / Employee (TTM)$-2,602,400
ROE (Last FY)-271.63%
Net Interest Coverage (Annual)-12.74x
EPS Basic Excl Extra (Annual)$-0.03
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$-0.02
ROI (TTM)-122.48%
P/S Ratio (TTM)6.86x
Pretax Margin (5Y Avg)-3976.65%
Revenue / Share (Annual)$0.05
Tangible BV / Share (Annual)$0.00
Price vs S&P 500 (52W)-42.06%
Year-to-Date Return-9.09%
5-Day Price Return0.00%
EPS Normalized (Annual)$-0.03
ROA (5Y Avg)-56.09%
Net Profit Margin (Annual)-585.00%
Month-to-Date Return0.00%
Cash Flow / Share (TTM)$-0.53
EBITD / Share (Annual)$-0.03
Operating Margin (Annual)-715.60%
LT Debt / Equity (Annual)0.68x
ROI (5Y Avg)-83.63%
LT Debt / Equity (Quarterly)0.56x
EPS Basic Excl Extra (TTM)$-0.02
P/TBV (Quarterly)2.67x
P/B Ratio (Annual)0.84x
Pretax Margin (TTM)-2781.60%
Book Value / Share (Annual)$0.01
Price vs S&P 500 (13W)-19.59%
Beta0.51x
Revenue / Share (TTM)$0.02
ROE (TTM)-123.62%
52-Week Low$1.00
vGradeB
gGradeD
mGradeC
vgmGradeC
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PPBTPurple Biotech Ltd. American Depositary Shares | B | D | C | $2.97 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Purple Biotech is a clinical-stage oncology company developing first-in-class therapies to overcome drug resistance and immune evasion in cancer. NT219, its lead small molecule candidate, targets IRS1/2 and STAT3 survival pathways associated with drug resistance, while CM24, a monoclonal antibody, blocks CEACAM1 to enhance anti-tumor immune response. Together, these programs address critical mechanisms that allow cancer cells to evade treatment.